Our data indicate that BB intervention inhibits TLR4 in chronic kidney disease, thereby augmenting the anti-inflammatory actions of Nrf2 over the pro-inflammatory actions of NFκB. This evidence concerns the gene NFKB1 and chronic kidney disease.